Sino Biopharmaceutical Limited (HKG:1177)

Sino Biopharmaceutical Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	2,343	3,500	2,332	2,544	14,608
Depreciation & Amortization	1,041	1,175	1,004	967.54	922.74
Other Amortization	170.1	145.7	70.05	79.45	129.82
Loss (Gain) From Sale of Assets	-11.17	-116.22	-62.69	-3.47	4.28
Asset Writedown & Restructuring Costs	71.92	305.43	-	19.4	492.1
Loss (Gain) From Sale of Investments	1,548	1,483	13.72	449.08	420.04
Loss (Gain) on Equity Investments	151.38	118.3	525.71	152.98	-13,631
Stock-Based Compensation	115.97	53.72	18.12	29.72	-
Provision & Write-off of Bad Debts	16.19	12.79	-12.26	3.93	1.62
Other Operating Activities	881.99	-257.16	2,316	1,655	2,757
Change in Accounts Receivable	615.19	-413.99	-816.03	-421.66	-1,308
Change in Inventory	116.48	-273.06	135.32	-391.1	-57.48
Change in Accounts Payable	-701.92	130.11	284.3	-55.8	-257.84
Change in Unearned Revenue	63.95	29.26	-142.32	74.62	66.25
Change in Other Net Operating Assets	2,869	714.15	108.21	598.34	1,218
Operating Cash Flow	9,292	6,615	6,066	6,265	5,366
Operating Cash Flow Growth	40.46%	9.06%	-3.18%	16.75%	0.77%

Investing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-1,239	-960.1	-1,068	-1,243	-1,714
Sale of Property, Plant & Equipment	48.73	70.85	100.99	27.89	132.2
Cash Acquisitions	-5,022	2.66	-1,157	-	-798.75
Divestitures	346.83	1,404	413.81	-146.17	-
Sale (Purchase) of Intangibles	-464.16	-434.06	-406.78	-302.94	-152.92
Investment in Securities	-7,975	-3,819	568.91	-3,703	-4,391
Other Investing Activities	1,891	2,026	790.43	1,297	4,408
Investing Cash Flow	-12,414	-1,709	-756.98	-4,071	-2,516

Financing Activities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Issued	-	-	-	-	136.13
Long-Term Debt Issued	13,601	11,696	12,194	9,753	1,270
Total Debt Issued	13,601	11,696	12,194	9,753	1,406
Long-Term Debt Repaid	-7,257	-14,475	-13,948	-8,790	-2,908
Net Debt Issued (Repaid)	6,344	-2,779	-1,754	962.99	-1,501
Repurchase of Common Stock	-110	-1,252	-396.39	-867.61	-332.93
Common Dividends Paid	-1,503	-1,846	-632.67	-1,268	-938.49
Other Financing Activities	-573.66	-437.24	-3,766	-2,014	-452.37
Financing Cash Flow	4,157	-6,315	-6,549	-3,186	-3,225

Net Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	118.07	135.52	90.52	47.32	-649.71
Net Cash Flow	1,153	-1,274	-1,150	-944.73	-1,025

Free Cash Flow

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	8,053	5,655	4,998	5,022	3,652
Free Cash Flow Growth	42.41%	13.15%	-0.48%	37.50%	-6.38%
Free Cash Flow Margin	25.30%	19.59%	19.08%	19.30%	13.60%
Free Cash Flow Per Share	0.45	0.31	0.27	0.26	0.19
Levered Free Cash Flow	6,601	3,905	3,006	2,991	-196.74
Unlevered Free Cash Flow	6,775	4,089	3,316	3,259	-3.85

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	273.91	287.25	480.83	339.52	179.62
Cash Income Tax Paid	1,604	1,001	746.57	892.09	726.72
Change in Working Capital	2,963	186.47	-430.51	-195.6	-339.14

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 21, 2026

Data Sources Report a data error